Reist 1989.

Methods	DESIGN Description: random‐assignment, placebo‐controlled, crossover, flexible dose, double‐blind, 4 day switched cross‐over, multi‐centre BLINDING Participants: Unclear Assessors: Unclear Administrators: Unclear ALLOCATION CONCEALMENT Method: No information RANDOMISATION Method: Unclear
Participants	SAMPLE Description: 27 DSM‐III PTSD, combat veterans, mean age 38.4 years (28‐64), all males, 33% (6/18) major depression, most prevalent comorbidity: 50% (9/18) dysthymic disorder, baseline severity on IES: desipramine (55.2) and placebo (56.2) SCREENING Primary diagnosis: Not mentioned Comorbidity: SCID, SCID ‐ DSM‐III‐R for personality disorders
Interventions	Description: desipramine 50 mg/d ‐200 mg/d (max avg: 165 mg/d) versus placebo x 8 weeks
Outcomes	HAM‐D, HAM‐A, BDI, IES (no distinction between primary and secondary outcomes) Data estimation: Completer values
Notes	INDUSTRY SUPPORT Industry funded: No information Medication provided by industry: Unclear Any of the authors work for industry: No ADDITIONAL INFORMATION Drop‐out rates: 33% (9/27) Quality rating score: 12 ongoing recreational and group therapies
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear